AMAG Pharmaceuticals (AMAG)
AMAG Pharmaceuticals R&D Expense: 12.46M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
AMAG R&D Expense Rankings
| Overall | 29th percentile | 1249 of 1764 |
| Sector | 28th percentile | 295 of 413 in Healthcare |
| Industry | 5th percentile | 16 of 17 in Diagnostic Substances |
AMAG R&D Expense Range, Past 5 Years
| Minimum | 4.823M | Mar 2008 |
| Maximum | 16.70M | Jun 2011 |
| Average | 10.56M |
About R&D Expense
R&D expenses are a line item from many companies' income statements.
R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.
Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.
An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More
You may also be interested in these AMAG related companies
AMAG News
AMAG (AMAG) Shares Collapse as Board Quietly Abandons Active Sale Process
May 10, 12:41PM Street Insider
May 10, 12:41PM Street Insider
Correction - Landenburg Thalmann Downgraded AMAG Pharmaceuticals (AMAG) to Hold
May 10, 8:41AM Street Insider
May 10, 8:41AM Street Insider
Baird Downgrades AMAG Pharmaceuticals (AMAG) to Neutral; Stepping To Sidelines As Risk Profile Increases
May 10, 8:06AM Street Insider
May 10, 8:06AM Street Insider
AMAG Pharmaceuticals Appoints William Heiden as President and Chief Executive Officer
May 09, 4:09PM Benzinga
May 09, 4:09PM Benzinga
Listen to $AMAG Q1 2012 earnings call - live at 04:30 PM, ondemand after - http://stks.co/3bwJ
about 26 days ago by earningscast
about 26 days ago by earningscast
AMAG Pharma (AMAG) Pops Higher on Positive CHMP Opinion for Ferumoxytol
Apr 20, 9:36AM Street Insider
Apr 20, 9:36AM Street Insider
AMAG Pharmaceuticals Announces a Positive CHMP Opinion for the Approval of Ferumoxytol in Europ
Apr 20, 9:33AM Benzinga
Apr 20, 9:33AM Benzinga
$AMAG forms bearish "Continuation Diamond" chart pattern. http://stks.co/3209
about 65 days ago by RecogniaEvents
about 65 days ago by RecogniaEvents
Baird Reiterates an 'Outperform' on AMAG Pharmaceuticals (AMAG); Positive IDA Trial De-Risks Major Opportunity
Mar 08, 10:02AM Street Insider
Mar 08, 10:02AM Street Insider
Listen to $AMAG Q4 2011 earnings call - live at 04:30 PM, ondemand after - http://stks.co/2gGF
about 83 days ago by earningscast
about 83 days ago by earningscast
$AMAG Q4 2011 Earnings Conference Call Mar.5th at 4:30 p.m. ET. Webcast @ http://stks.co/2f03
about 85 days ago by abubnic
about 85 days ago by abubnic
$AMAG Ceo will participate at the 24th Annual ROTH Conference on Mar 13 at 4:30 pm PT. Webcast @ http://stks.co/2f00
about 85 days ago by abubnic
about 85 days ago by abubnic
$AMAG Downside Blowoff - 15 Minute Up Reversal - Green bar after 5 red bars
about 139 days ago by TradeIdeasQuant
about 139 days ago by TradeIdeasQuant
$AMAG "No serious adverse events were reported" in results of test on company's ferumoxytol
about 167 days ago by Benzinga
about 167 days ago by Benzinga
If you were patient enough to hold onto $amag through the summer/fall you are up pretty nicely
about 172 days ago by DavidSchawel
about 172 days ago by DavidSchawel
$AMAG 200 Day SMA Cross - Price crossed below 200 day SMA (16.1075). Confirmed by volume.
about 192 days ago by TradeIdeasQuant
about 192 days ago by TradeIdeasQuant
AMAG Pharmaceuticals $AMAG up 4% after hiring Jefferies to explore options, including a potential sale.
about 192 days ago by Street_Insider
about 192 days ago by Street_Insider
15 breakouts: $AMAG (200-day MA + gap + base), $MXWL (stop: $17.99), $MDAS (gap). Two sub-$1. Okay mix of stocks if some are extended.
about 203 days ago by fallondpicks
about 203 days ago by fallondpicks
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AMAG | 13.90 | +0.35 | +2.58% | 294.68M |
| AM | 14.27 | -0.10 | -0.70% | 546.83M |
| ALXN | 92.42 | -0.68 | -0.73% | 17.19B |
| ALX | 391.06 | +0.06 | +0.02% | 1.998B |
| ALVR | 0.49 | +0.03 | +6.52% | 28.41M |
| AMNB | 22.00 | -0.24 | -1.08% | 172.26M |
| AMLP | 15.95 | +0.05 | +0.31% | |
| AMLN | 27.96 | +2.16 | +8.37% | 4.496B |
| AMKR | 4.65 | +0.07 | +1.53% | 782.83M |
| AMJ | 37.36 | +0.23 | +0.62% |
